Department of Urology, Chung-Ang University Gwangmyeoung Hospital, Gwangmyeoung, Korea.
Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Investig Clin Urol. 2022 Jul;63(4):373-384. doi: 10.4111/icu.20220061. Epub 2022 May 30.
In the past, there was no second-line chemotherapeutic agent suitable for use when urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several new treatment options, such as immune checkpoint inhibitors or targeted therapy have shifted the treatment paradigm regarding second-line therapeutic modalities. A novel class of therapeutic agents includes an antibody-drug conjugate (ADC). ADCs consist of three characteristics: a monoclonal antibody, linker, and payload. The specificity of the monoclonal antibody facilitates the delivery of a linked cytotoxic drug directly into the target tumor cell. Although various ADCs have been developed and approved for use in treating several solid tumors, almost all ADCs for the treatment of UC are still in the testing phase. Here, we review the key points about ADCs and summarize the novel ADCs that are approved or are involved in ongoing studies in UC.
在过去，当尿路上皮癌（UC）进展为铂类耐药 UC 时，没有合适的二线化疗药物。然而，最近，一些新的治疗选择，如免疫检查点抑制剂或靶向治疗，已经改变了二线治疗模式。一类新的治疗药物包括抗体药物偶联物（ADC）。ADC 由三个特点组成：单克隆抗体、连接子和有效载荷。单克隆抗体的特异性有助于将连接的细胞毒性药物直接递送至靶肿瘤细胞。尽管已经开发并批准了多种 ADC 用于治疗几种实体瘤，但几乎所有用于 UC 治疗的 ADC 仍处于试验阶段。在这里，我们回顾了 ADC 的要点，并总结了已批准或正在 UC 研究中进行的新型 ADC。
